India to consider raft of new compulsory licencesBMJ 2014; 348 doi: https://doi.org/10.1136/bmj.g1094 (Published 24 January 2014) Cite this as: BMJ 2014;348:g1094
- Sanjeet Bagcchi
A government appointed panel is set to review over 20 drug patents in India and recommend compulsory licensing so that the country’s generic drug manufacturers can produce the drugs at low cost, the magazine Bloomberg Businessweek has reported.1
The BMJ has found Indian media and the government silent on this issue. To date no announcement or document on this initiative has officially emerged. However, the Bloomberg Businessweek article quoted two anonymous sources who acknowledged the plans.
The article said, “The panel is looking beyond the cancer treatments it studied last year to areas such as HIV and diabetes, according to two people with knowledge of the matter, …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial